Literature DB >> 16623638

Construction and characterization of feline immunodeficiency virus proviral mutants that coexpress interferon gamma and green fluorescent protein.

Soumi Gupta1, Christian Leutenegger, Gregg Dean, Ellen Sparger.   

Abstract

Vif deletion mutants of the feline immunodeficiency virus (FIV) were designed to express either enhanced green fluorescent protein (EGFP) (FIVdeltavifATGgfp) or feline interferon-gamma (IFN-gamma) (FIVdeltavifATGgamma) by insertion of the nonviral gene into the deletion site of the viral vif gene. Two in-frame start codons within vif were mutated without altering the overlapping pol translation frame to enhance expression of inserted genes. Expression of EGFP and IFN-gamma from FIVdeltavifATGgfp and FIVdeltavifATGgamma proviruses, respectively, was confirmed by fluorescent microscopy and immunocytochemical assays, respectively. Replication of viruses generated from these proviruses was detectable but severely restricted when compared to that of wild-type (WT) FIV-pPPR. A previous study demonstrated induction of protection against homologous FIV challenge by vaccination of cats with an attenuated FIV-pPPRdeltavif proviral DNA vaccine (Lockridge K et al.: Virology 2000;273:67-79). Coexpression of IFN-gamma or other cytokines from this attenuated provirus provides the opportunity to evaluate the ability of an immunomodulator to enhance the safety and efficacy of an infectious attenuated DNA vaccine. Moreover, a vif-deleted FIV provirus that coexpresses a reporter gene such as EGFP may be used to examine the localization of vif mutant viruses in vivo.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16623638     DOI: 10.1089/aid.2006.22.342

Source DB:  PubMed          Journal:  AIDS Res Hum Retroviruses        ISSN: 0889-2229            Impact factor:   2.205


  1 in total

1.  Vaccination of cats with attenuated feline immunodeficiency virus proviral DNA vaccine expressing gamma interferon.

Authors:  Soumi Gupta; Christian M Leutenegger; Gregg A Dean; Jonathan D Steckbeck; Kelly Stefano Cole; Ellen E Sparger
Journal:  J Virol       Date:  2006-11-01       Impact factor: 5.103

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.